Factors associated with initiation of bone-health medication among older adults in primary care in Ireland
暂无分享,去创建一个
[1] Marrissa Martyn-St James,et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. , 2020, Health technology assessment.
[2] N. Watts,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[3] J. Thistlethwaite,et al. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice , 2020, BMC Family Practice.
[4] A. Gafter-Gvili,et al. Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-analysis. , 2020, The Journal of clinical endocrinology and metabolism.
[5] K. Johnell,et al. Polypharmacy and injurious falls in older adults: a nationwide nested case-control study , 2019, Clinical epidemiology.
[6] J. Quinlan,et al. Changing trends in the mortality rate at 1-year post hip fracture - a systematic review , 2019, World journal of orthopedics.
[7] H. E. van der Horst,et al. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study , 2018, BMC Family Practice.
[8] C. Cooper,et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.
[9] C. Cooper,et al. UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.
[10] K. Robinson,et al. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease , 2017, Annals of Internal Medicine.
[11] S. Greenspan,et al. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Geriatrics Society.
[12] Ran D Balicer,et al. External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study , 2017, British Medical Journal.
[13] S. Davis,et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. , 2016, Health technology assessment.
[14] L. A. A. Santos,et al. Diagnosis and Management of Cirrhosis-Related Osteoporosis , 2016, BioMed research international.
[15] Lorena Saletti-Cuesta,et al. The relevance of gender in the care of hip fracture patients. , 2016, International journal of orthopaedic and trauma nursing.
[16] A. Pabst,et al. Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw , 2016, Dentistry journal.
[17] M. Price,et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. , 2016, Health technology assessment.
[18] E. Siris,et al. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage , 2015, Clinical interventions in aging.
[19] David Moher,et al. The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.
[20] L. Carmona,et al. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.
[21] James R. Rogers,et al. Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis , 2015, PloS one.
[22] J. Reginster,et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. , 2015, The Journal of clinical endocrinology and metabolism.
[23] L. Melton,et al. Trends in Fracture Incidence: A Population‐Based Study Over 20 Years , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] R. Eastell,et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.
[25] Carol Coupland,et al. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.
[26] J. Kanis,et al. From relative risk to absolute fracture risk calculation: The FRAX algorithm , 2009, Current osteoporosis reports.
[27] L. Ji,et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. , 2019, Bone.
[28] S. Straus,et al. Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis , 2017, Osteoporosis International.
[29] N. Watts,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[30] C. Cunningham,et al. Awareness and management of osteoporosis among General Practitioners in Ireland , 2015 .